drugset / Trial / NCT03673956

Topical Antibiotics in Chronic Rhinosinusitis

NCT03673956

Phase 1/2 Completed 19 enrolled Mayo Clinic
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Researchers are trying to find out if patients develop antibiotic resistant organisms after the use of topical antibiotics in the treatment of chronic rhinosinusitis.

Timeline

Start
2018-09-26
Primary completion
2021-02-01
Completion
2021-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Levofloxacin Small molecule 240 mg Intranasal
Subject Mupirocin Small molecule 30 mg Intranasal
Subject Tobramycin Small molecule 240 mg Intranasal
Subject Vancomycin Other / unclassified 240 mg Intranasal